13kAccesses
317Altmetric
42Mentions
Abstract
Owing to the high diversity of terrestrial and marine organisms, natural products (secondary metabolites) are some of the most successful source of drug leads for the treatment of many diseases and illnesses. In the 1990s, advancements in automation [high-throughput screening (HTS)] and isolation technologies resulted in the surge in research towards natural products both in the fields of human health and agriculture. These strategies and techniques generated a substantial shift towards this ‘green Eldorado’, a real ‘Green Rush’ between 1990 and 2000. However, in the early 2000s most of the big Pharmas terminated their HTS and bioprospecting endeavours but to date, the low productivity of combichem and rational drug design is silently positioning pharmacognosy back on the rails and natural product discovery is remerging as a reputable source of current drugs on the market. Meanwhile, the World Health Organization has come to the realisation of the importance of biodiversity which would be able to offer affordable, therapeutic solutions to the majority of the world population. The preservation of the world’s biodiversity and its access is a critical issue which could hamper a serene utilisation of natural products in the developing world with herbal-based phytopharmaceuticals representing a significant share of the total world pharmaceutical market. This review presents an industrial perspective discussing natural product drug discovery, lead research, botanicals, pro-drugs, synergy effects, drugs interactions with botanicals, traditional medicines, reverse pharmacognosy and presents the difficulties in accessing biodiversity.
This is a preview of subscription content,log in via an institution to check access.
Access this article
Subscribe and save
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime
Buy Now
Price includes VAT (Japan)
Instant access to the full article PDF.

Similar content being viewed by others
References
Anonymous (1992) United Nations. Convention on biological diversity.http://www.cbd.int/doc/legal/cbd-en.pdf. Cited 20 May 2014
Anonymous (1973) Art 53 c of the The European Patent Convention,http://www.epo.org/law-practice/legal-texts/html/epc/2010/e/ar53.html Cited 20 May 2014
Anonymus (2011) The Nagoya protocol on access to genetic resources and the fair and equitable sharing of benefits arising from their utilization to the convention on biological diversity.http://www.cbd.int/abs/doc/protocol/nagoya-protocol-en.pdf. Cited 20 May 2014
Attinger P (2008) La médecine mésopotamienne. Journal des Médecines Cunéiformes 11–12:1–96
Baker DD (2007) The value of natural products to future pharmaceutical discovery. Nat Prod Rep 27:1225–1244
Bauer RA, Wurst JM, Tan DS (2010) Expanding the range of ‘druggable’ targets with natural product-based libraries: an academic perspective. Curr Opin Chem Biol 14:308–314
Berenbaum MC (1989) What is Synergy? Pharmacol Rev 41:93–141
Beutler JA (2009) Natural products as a foundation for drug discovery. Curr Protoc Toxicol Supplement 46:9.11.1–9.11.21
Bhatnagar I, Se-Kwon K (2010) Marine antitumor drugs: status, shortfalls and strategies. Mar Drugs 8:2702–2720
Blunt JW, Copp BR, Munro MHG et al (2011) Marine natural products. Nat Prod Rep 28:196–268
Bruneton J (2009) Pharmacognosie, phytochimie, plantes médicinales. Paris, Tec & Doc – Lavoisier
Bunnage ME (2011) Getting pharmaceutical R&D back on target. Nat Chem Biol 7:335–339
Buriani A, Garcia-Bermejo ML, Bosisio E et al (2012) Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol 140:535–544
Butler MS (2005) Natural products to drugs: natural products derived compounds in clinical trials. Nat Prod Rep 22:162–195
Challal S, Bohni N, Buenafe OE et al (2012) Zebrafish bioassay-guided microfractionation for the rapid in vivo identification of pharmacologically active natural products. Chimia 66:229–232
Chen S-L, Jiang J-G (2012) Application of gene differential expression technology in the mechanism studies of nature product-derived drugs. Expert Opin Biol Ther 12:823–839
Chen ST, Dou J, Temple R et al (2008) New therapies from old medicines. Nat Biotechnol 26:1077–1083
Chen CH, Dickman KG, Moriya M et al (2012) Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 109:8241–8246
Colegate SM, Molyneux RJ (2008) Bioactive natural products: Detection, isolation and structure determination. CRC Press, Boca Raton
Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461–477
Cragg GM, Newman DJ (2013) Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 1830:3670–3695
Cragg GM, Newman DJ, Snader KM (1997) Natural products in drug discovery and development. J Nat Prod 60:52–60
Cuevas C, Francesch A (2009) Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Nat Prod Rep 26:322–337
Dančík V, Seiler KP, Young DW et al (2010) Distinct biological network properties between the targets of natural products and disease genes. J Am Chem Soc 132:9259–9261
David B, Ausseil F (2014) David B, Ausseil F (2014) Chapter 44. In: Hostettmann J, Stuppner H, Marston A, Chen S (eds) Handbook of chemical and biological plant analytical methods, 1st edn. Wiley, New Jersey
Dewick PM (2009) Medicinal natural products: A biosynthentic approach, 3rd edn. Wiley, Great Britain
Dias DA, Urban S, Roessner U (2012) A historical overview of natural products in drug discovery. Metabolites 2:303–336
Dickson M, Gagnon JP (2004) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3:417–429
Eldridge GR, Vervoort HC, Lee CM et al (2002) High-Throughput Method for the Production and Analysis of Large Natural Product Libraries for Drug Discovery. Anal Chem 74:3963–3971
Erkens RHJ (2011) What every chemist should know about plant names. Nat Prod Rep 28:11–14
Farnsworth NR (1990) The role of ethnopharmacology in drug development. In: Chadwick DJ, Marsh J (eds) Bioactive compounds from plants. John Wiley and Sons, Chichester
Feher M, Schmidt JM (2003) Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Inf Comput Sci 43:218–227
Fitzgerald JB, Schoeberl B, Nielsen UB et al (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2:458–466
Frearson JA, Collie IT (2009) HTS and hit finding in academia–from chemical genomics to drug discovery. Drug Discov Today 14:1150–1158
Genilloud O (2012) Current challenges in the discovery of novel antibacterials from microbial natural products. Recent Patents on Anti-Infective Drug Dis 7:189–204
Gertsch J (2011) Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Plant Med 77:1086–1098
Gilbert N (2010) Biodiversity law could stymie research. Nature 463:598
Gilbert N (2012) Chinese herbal medicine breaks into EU market. Nature News Blog,http://blogs.nature.com/news/2012/04/chinese-herbal-medicine-breaks-into-eu-market.html Cited 20 May 2014
Hammerness P, Basch E, Ulbricht C et al (2003) St. John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 44:271–282
Harvey AL (2008) Natural products in drug discovery. Drug Discovery Today 13:894–901
Helmstädter A, Staiger C (2013) Traditional use of medicinal agents: a valid source of evidence. Drug Discovery Today 19:4–7
Hoffman F, Kishter SR (2013) Botanical new drug applications - The Final Frontier. Herbalgram 99:66–69
Hong J (2011) Role of natural product diversity in chemical biology. Curr Opin Chem Biol 15:350–354
Jiang GC, Lin YC, Zhou SN et al (2000) Acta Sci. Nat. Univ. Sunyatseni 39:68
Jiang Y, David B, Tu PF et al (2010) Recent analytical approaches in quality control of traditional Chinese medicines- A review. Anal Chim Acta 657:9–18
Kingston DGI (2011) Modern natural products drug discovery and its relevance to biodiversity cConservation. J Nat Prod 74:496–511
Kleinrock M (2012) IMS institute for healthcare informatics—The global use of medicines: Outlook through 2016.www.theimsinstitute.org. Cited 20 May 2014
Koehn FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4:206–220
Krohn K, Dai JQ, Floerke U et al (2005) Botryane metabolites from the fungusGeniculosporium sp. isolated from the marine red algaPolysiphonia. J Nat Prod 68:400–405
Kusari S, Hertweck C, Spiteller M (2012) Chemical ecology of endophytic fungi: origins of secondary metabolites. Chem Biol 19:792–798
Lamottke K, Ripoll C, Walczak R (2011) The roots of innovation. European Biopharmaceutical Review 15:52–56
Lauro G, Masullo M, Piacente S et al (2012) Inverse virtual screening allows the discovery of the biological activity of natural compounds. Bioorg & Med Chem 20:3596–3602
Lawson K (2013) Botanical and plant-derived drugs: Global markets. BCC Research, Wellesley
Li YG, Huang WJ, Huang SY et al (2012) Screening of anti-cancer agent using zebrafish: comparison with the MTT assay. Biochem Biophys Res Comm 422:85–90
Macarrón R, Banks MN, Bojanic D et al (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10:188–195
Mackay M (1998) Prescribed drugs: a major cause of ill health. Aust Health Rev 21:260–266
Matias EFF, Alves EF, Santos BS et al (2013) Biological activities and chemical characterization ofCordia verbenacea DC. as tool to validate the ethnobiological usage. Evid Based Complement Alternat Med 2013:164215
Mayer AM, Glaser KB, Cuevas C et al (2010) The odyssey of marine pharmaceuticals: a current pipeline perspective. Trends Pharmacol Sci 31:255–265
McChesney JD, Venkataraman SK, Henri JT (2007) Plant natural products: back to the future or into extinction? Phytochemistry 68:2015–2022
McWilliams A (2006) Plant-derived drugs: Products, technology, applications (BIO022D) BBC Research,http://www.bbcresearch.com Cited 20 May 2014
Michael S, Auld D, Klumpp C et al (2008) A robotic platform for quantitative high-throughput screening. Assay Drug Dev Technol 6:637–657
Miller JS (2011) The discovery of medicines from plants: a current biological perspective. Econ Bot 65:396–407
Mishra BB, Tiwari VK (2011) Natural products: an evolving role in future drug discovery. Euro J Med Chem 46:4769–4807
Muller WE, Singer A, Wonnemann M (2001) Hyperforin - Antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 34(suppl1):S98–S102
Naoghare PK, Song JM (2010) Chip-based high throughput screening of herbal medicines. Comb Chem High Throughout Screen 13:923–931
Newman DJ (2008) Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J Med Chem 51:2589–2599
Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70:461–477
Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311–335
Newman DJ, Cragg GM, Snader KM (2003) Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 66:1022–1037
Ngo LT, Okogun JI, Folk WR (2013) 21st century natural product research and drug development and traditional medicines. Nat Prod Rep 30:584–592
Nicoletti M (2012) Nutraceuticals and botanicals: overview and perspectives. Int J Food Sci Nutr 63:2–6
Novodvorsky P, Da Costa MMJ, Chico TJA (2013) Zebrafish-based small molecule screens for novel cardiovascular drug. Drug Discov Today 10:e109–e114
Ortholand J-Y, Ganesan A (2004) Natural products and combinatorial chemistry: back to the future. Curr Opin Chem Biol 8:271–280
Paterson I, Anderson EA (2005) The renaissance of natural products as drug candidates. Science 310:451–453
Posadzki P, Watson L, Ernst E (2013) Herbdrug interactions: an overview of systematic reviews. Br J Clin Pharmacol 75:603–618
Ribnicky DM, Poulev A, Schmidt B et al (2008) Evaluation of botanicals for improving human health. Am J Clin Nutr 87:472S–475S
Roessner U (2011) Metabolomics – The combination of analytical chemistry, biology and informatics. In: Moo-Young M (ed) Comprehensive Biotechnology, 2nd edn. Springer, Heidelberg, Germany
Rollinger JM (2011) Combination of ethnopharmacological knowhow with modern in silico tools. Planta Med 77:1230
Rollinger JM, Langer T, Stuppner H (2006) Strategies for efficient lead structure discovery from natural products. Curr Med Chem 13:1491–1507
Saklani A, Kutty SK (2008) Plant-derived compounds in clinical trials. DDT 13:161–171
Sativex (2013)http://www.sativex.co.uk/healthcare-professionals Cited 27 Oct 2013
Scheinfeld N (2008) Sinecatechins. Drugs Fut 33:27–30
Schmidt B, Ribnicky DM, Poulev A et al (2008) A natural history of botanical therapeutics. Metabolism 57:S3–S9
Schmitt EK, Moore CM, Krastel P et al (2011) Natural products as catalysts for innovation: a pharmaceutical industry perspective. Curr Opin Chem Biol 15:497–504
Sheridan C (2012) Recasting natural product research. Nat Biotechnol 30:385–387
Sertürner F (1817) Über das Morphium, eine neue salzfähige Grundlage und die Mekonsäure, als Hauptbestandtheile des Opiums. Ann Phys 55:56–89
Stickel F, Patsenker E, Schuppan D (2005) Herbal hepatotoxicity. J Hepatol 43:901–910
Swinney DC, Anthony J (2011) How where new medicine discovered? Nat Rev Drug Discov 10:507–519
Thomas GL, Johannes CW (2011) Natural product-like synthetic libraries. Curr Opin Chem Biol 15:516–522
U.S. Food and Drug Administration (2013) News and Events, FDA News Release (2012) FDA approves first anti-diarrheal drug for HIV/AIDS patients.http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333701.htm. Cited 20 May 2014
van der Kooy F, Maltese F, Hae Choi Y et al (2009) Quality control of herbal material and phytopharmaceuticals with MS and NMR based metabolic fingerprinting. Planta Med 75:763–775
van Wietmarschen H, Yuan K, Lu C et al (2009) Systems Biology Guided by Chinese Medicine Reveals New Markers for Sub-Typing Rheumatoid Arthritis Patients. J Clin Rheumatol 15:330–337
Verpoorte R (2012) Good Practices: the basis for evidence-based medicines. J Ethnopharmacol 140:455–457
Verpoorte R, Choi YH, Kim HK (2005) Ethnopharmacology and systems biology: a perfect holistic match. J Ethnopharmacol 100:53–56
Verpoorte R, Crommelin D, Danhof M et al (2009) Commentary: “A systems view on the future of medicine: inspiration from Chinese medicine?”. J Ethnopharmacol 121:479–481
Wagner H (2005) Natural products chemistry and phytomedicine in the 21st century: new developments and challenges. Pure Appl Chem 77:1–6
Wagner H (2011) Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia 82:34–37
Wagner H, Ulrich-Merzenich G (2009) Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine 16:97–110
Wang L, Chen C (2013) Emerging applications of metabolomics in studying chemopreventive phytochemicals. Aaps Journal 15:941–950
Wang M, Lamers R, Korthout H et al (2005a) Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res 19:173–182
Wang Y, Tang H, Nicholson JK et al (2005b) A metabonomic strategy for the detection of the metabolic effects of chamomile (Matricaria recutita L.) ingestion. J Agric Food Chem 53:191–196
Woelk H (2000) Comparison of St John’s wort and imipramine for treating depression: randomised controlled trial. BMJ 321:536–539
Wolfender J-L, Eugster PJ, Bohni N et al (2011) Advanced methods for natural product drug discovery in the field of nutraceuticals. Chimia 65:400–406
Xie G, Li X, Li H et al (2013) Toward personalized nutrition: comprehensive phytoprofiling and metabotyping. J Proteome Res 12:1547–1559
Yang M, Poon J, Wang S et al (2013) Application of Genetic Algorithm for Discovery of Core Effective Formulae in TCM Clinical Data. Comp. Math. Methods in Medicine 2013:1–16
Yuliana ND, Khatib A, Choi YH et al (2011) Metabolomics for bioactivity assessment of natural products. Phytother Res 25:157–169
Zhang HW, Song YC, Tan RX (2006) Biology and chemistry of endophytes. Nat Prod Rep 23:753–771
Zhang B, Peng Y, Zhang Z et al (2010) GAP production of TCM herbs in China. Planta Med 76:1948–1955
Zheng BC (1988) The earliest monograph on pharmaceuticals in China. J Tradit Chin Med 8:75–76
Conflict of interest
The authors state no conflict of interest and have received no payment in preparation of this manuscript.
Author information
Authors and Affiliations
Pôle Actifs Végétaux - Branche Sourcing R&D et Botanique, Institut de Recherche Pierre FABRE, 3, Avenue Hubert Curien - BP 13562, 31562, Toulouse, Cedex, France
Bruno David
Phytochemistry and Bioactive Natural Products, School of Pharmaceutical Sciences, University of Geneva and University of Lausanne, Quai Ernest-Ansermet 30, CH-1211, Geneva, Switzerland
Jean-Luc Wolfender
Metabolomics Australia, School of Botany, The University of Melbourne, Parkville, Victoria, 3010, Australia
Daniel A. Dias
- Bruno David
You can also search for this author inPubMed Google Scholar
- Jean-Luc Wolfender
You can also search for this author inPubMed Google Scholar
- Daniel A. Dias
You can also search for this author inPubMed Google Scholar
Corresponding author
Correspondence toJean-Luc Wolfender.
Rights and permissions
About this article
Cite this article
David, B., Wolfender, JL. & Dias, D.A. The pharmaceutical industry and natural products: historical status and new trends.Phytochem Rev14, 299–315 (2015). https://doi.org/10.1007/s11101-014-9367-z
Received:
Accepted:
Published:
Issue Date: